Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Letter to the Editor

Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD

Shuhei Fukunaga, Michita Mukasa, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(1):121-123. Published online December 4, 2023

DOI: https://doi.org/10.3350/cmh.2023.0437

View: 1622 Download: 73 Web of Science: 5 Crossref: 2

Review

Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments

Sang Bong Ahn

Clin Mol Hepatol. 2023;29(Suppl):S150-S156. Published online January 25, 2023

DOI: https://doi.org/10.3350/cmh.2022.0362

View: 3898 Download: 227 Web of Science: 7 Crossref: 8

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima

Clin Mol Hepatol. 2023;29(Suppl):S123-S135. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0357

View: 4082 Download: 197 Web of Science: 11 Crossref: 12

Original Article

Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity

Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe

Clin Mol Hepatol. 2023;29(4):987-1001. Published online July 5, 2023

DOI: https://doi.org/10.3350/cmh.2023.0035

View: 4008 Download: 272 Web of Science: 8 Crossref: 8

Editorial

From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials

Ming-Lun Yeh, Ming-Lung Yu

Clin Mol Hepatol. 2023;29(4):969-972. Published online September 18, 2023

DOI: https://doi.org/10.3350/cmh.2023.0359

View: 2221 Download: 160 Web of Science: 4 Crossref: 4

The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B

Xianhua Mao, Lung Yi Mak, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(3):690-692. Published online May 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0173

View: 2110 Download: 93 Web of Science: 1 Crossref: 1

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Lynna Alnimer, Mazen Noureddin

Clin Mol Hepatol. 2023;29(2):394-397. Published online April 1, 2023

DOI: https://doi.org/10.3350/cmh.2023.0104

View: 2711 Download: 86 Web of Science: 1

Original Article

Gut-derived lipopolysaccharide promotes alcoholic hepatosteatosis and subsequent hepatocellular carcinoma by stimulating neutrophil extracellular traps through toll-like receptor 4

Yang Liu, Xin Zhang, Shuo Chen, Jiazhong Wang, Shuo Yu, Yiming Li, Meng Xu, Harouna Aboubacar, Junhui Li, Tao Shan, Jixin Wang, Gang Cao

Clin Mol Hepatol. 2022;28(3):522-539. Published online May 4, 2022

DOI: https://doi.org/10.3350/cmh.2022.0039

View: 5216 Download: 186 Web of Science: 16 Crossref: 18

Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis

Gang Xu, Yu-Min Wang, Miao-Miao Ying, Sui-Dan Chen, Zong-Rui Li, Hong-Lei Ma, Ming-Hua Zheng, Jian Wu, Chunming Ding

Clin Mol Hepatol. 2021;27(2):329-345. Published online January 20, 2021

DOI: https://doi.org/10.3350/cmh.2020.0261

View: 7192 Download: 226 Web of Science: 14 Crossref: 16

Liver Imaging

Chemotherapy induced liver abnormalities: an imaging perspective

Ankush Sharma, Roozbeh Houshyar, Priya Bhosale, Joon-Il Choi, Rajesh Gulati, Chandana Lall

Clin Mol Hepatol. 2014;20(3):317-326. Published online September 25, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.3.317

View: 15402 Download: 313 Web of Science: 59 Crossref: 55

Review

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

The Korean Association for the Study of the Liver (KASL)

Clin Mol Hepatol. 2013;19(4):325-348. Published online December 28, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.4.325

View: 13731 Download: 161 Crossref: 95

5

Fatty Liver

So Young Jin

Clin Mol Hepatol. 2006;12(1):112-115. Published online January 1, 1970

View: 2297 Download: 13

Letter to the Editor

Changing from NAFLD to MASLD: Cumulative incidence of gallstones between patients with NAFLD and those with MASLD in Asia

Shuhei Fukunaga, Tomoyuki Nakane, Michita Mukasa, Hidetoshi Takedatsu, Takumi Kawaguchi

Received April 7, 2024 Accepted May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0233 [Accepted]

View: 382 Download: 30 Crossref: 1

Equivalent Prevalence and Progression of Chronic Kidney Disease in NAFLD and MASLD

Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi

Received April 15, 2024 Accepted May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0264 [Accepted]

View: 433 Download: 50

1 |

Viewed By 5505	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5409	MAFLD: How is it different from NAFLD?
Viewed By 5220	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5098	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4732	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 90	MAFLD: How is it different from NAFLD?
Cited By 80	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search